Urologikum Hamburg MVZ
- Address
- lock Available on a paid plan
Urologikum Hamburg MVZ - Urological Oncology Research
Urologikum Hamburg MVZ is a specialized medical care center dedicated to advancing urological cancer treatment through innovative clinical research. The center focuses on developing novel therapeutic approaches for bladder cancer, with particular expertise in targeted therapies and intravesical treatment modalities.
- Non-muscle invasive bladder cancer with FGFR gene alterations
- Targeted intravesical drug delivery systems
- Precision medicine approaches in urological oncology
The center's research program emphasizes intermediate-risk bladder cancer management, investigating advanced treatment options for patients with FGFR+ tumors. By participating in comparative effectiveness trials, Urologikum Hamburg MVZ contributes to the development of personalized treatment strategies that aim to improve disease-free survival outcomes while minimizing treatment burden for patients with non-muscle invasive bladder cancer.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Urologikum Hamburg MVZ
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Open-Label Extension Study on Long-Term Safety of Enzalutamide in Prostate Cancer Patients from Previous Clinical Trials | Astellas Pharma Global Development Inc. | Phase II | Recruiting | Nov 2016 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abiraterone | 1 | Unknown | 2016-11-29 | 2016-11-29 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.